Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Buy

Analyst Rating

Sell

Simple Moving Average

Buy

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Neutral

B

Agenus Inc. (AGEN)

Biological Products, (no Disgnostic Substances)

https://www.agenusbio.com

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

3 FORBES ROAD
LEXINGTON, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

02/04/2000

Market Cap

113,899,632

Shares Outstanding

381,500,000

Weighted SO

381,495,471

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

ICVX --.--%

GRTX --.--%

MRKR --.--%

EWTX --.--%

ADAP --.--%

MREO --.--%

PIRS --.--%

PDSB --.--%

LPTX --.--%

Beta

1.3170

Last Div

0.0000

Range

4.41-32.0

Chg

0.1100

Avg Vol

820553

Mkt Cap

113899632

Exch

NASDAQ

Country

US

Phone

781 674 4400

DCF Diff

16.9131

DCF

-6.0931

Div Yield

0.0000

P/S

0.7135

EV Multiple

-4.3815

P/FV

-0.4608

Div Yield %

0.0000

P/E

-0.4977

PEG

-0.0387

Payout

0.0000

Current Ratio

0.3695

Quick Ratio

0.3695

Cash Ratio

0.3463

DSO

1.6440

DIO

0.0000

Op Cycle

1.6440

DPO

289.2138

CCC

-287.5698

Gross Margin

0.5980

Op Margin

-0.7127

Pretax Margin

-1.4494

Net Margin

-1.3999

Eff Tax Rate

-0.0483

ROA

-0.7642

ROE

1.2208

ROCE

-5.2313

NI/EBT

0.9658

EBT/EBIT

2.0335

EBIT/Rev

-0.7127

Debt Ratio

1.2168

D/E

-1.4745

LT Debt/Cap

-3.2230

Total Debt/Cap

3.1076

Int Coverage

-1.8674

CF/Debt

-0.5115

Equity Multi

-1.2118

Rec Turnover

222.0153

Pay Turnover

1.2620

Inv Turnover

0.0000

FA Turnover

1.0198

Asset Turnover

0.5459

OCF/Share

-8.6413

FCF/Share

-8.5832

Cash/Share

4.4499

OCF/Sales

-1.1402

FCF/OCF

0.9933

CF Coverage

-0.5115

ST Coverage

-1.0604

CapEx Coverage

-148.5747

Div&CapEx Cov

-148.5747

P/BV

-0.4608

P/B

-0.4608

P/S

0.7135

P/E

-0.4977

P/FCF

-0.6300

P/OCF

-0.6110

P/CF

-0.6110

PEG

-0.0387

P/S

0.7135

EV Multiple

-4.3815

P/FV

-0.4608

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Oct 30, 22:54 Agenus Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 5, 2024 Deadline to file Lead Plaintiff Motion GlobeNewswire Inc. Oct 30, 01:00 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GitLab, Allarity, ZoomInfo, and Agenus and Encourages Investors to Contact the Firm GlobeNewswire Inc. Oct 29, 00:43 Agenus Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 5, 2024 Deadline to file Lead Plaintiff Motion. GlobeNewswire Inc. Sep 29, 21:43 ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Agenus Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AGEN GlobeNewswire Inc. Sep 21, 00:05 AGEN Class Action Notice: Robbins LLP Reminds Agenus Inc. Stockholders of Pending AGEN Class Action Lawsuit GlobeNewswire Inc. Sep 15, 20:00 AGEN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Agenus Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! Zacks Investment Research Dec 26, 10:10 Merck (MRK) & Daiichi Sankyo's Lung Cancer ADC Gets Priority Tag The Motley Fool Dec 24, 09:45 2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street The Motley Fool Dec 24, 09:45 2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street The Motley Fool Dec 24, 09:45 2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street The Motley Fool Dec 24, 09:45 2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street The Motley Fool Dec 24, 09:45 2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street The Motley Fool Dec 24, 09:45 2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street The Motley Fool Dec 24, 09:45 2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street The Motley Fool Dec 24, 09:45 2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street The Motley Fool Dec 24, 09:45 2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street The Motley Fool Dec 24, 09:45 2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street The Motley Fool Dec 24, 09:45 2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street The Motley Fool Dec 24, 09:45 2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street The Motley Fool Dec 24, 09:45 2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street

Revenue Product Segmentation